← Back to Search

Mindfulness-Based Interventions for Obsessive-Compulsive Disorder (MindOC Trial)

N/A
Recruiting
Led By Neil A Rector, PhD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights

MindOC Trial Summary

This trial is testing whether mindfulness can be an effective treatment for OCD by reducing the suffering associated with the disorder.

Who is the study for?
This trial is for adults with OCD who have significant symptoms (YBOCS score > 17) and are stable on their current medication dose for at least 8 weeks. It's not suitable for those with severe mood disorders, schizophrenia, substance abuse issues, or urgent medical conditions.Check my eligibility
What is being tested?
The study tests if Mindfulness-Based Cognitive Therapy (MBCT), possibly using a device called Muse, can help reduce OCD symptoms compared to standard Cognitive Behaviour Therapy (CBT). Participants will be randomly assigned to one of the treatments in this large-scale trial.See study design
What are the potential side effects?
While MBCT and CBT generally have minimal side effects compared to medication, some may experience temporary increases in anxiety or distress when confronting obsessive thoughts without engaging in compulsions.

MindOC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in OCD symptom severity, as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)
Secondary outcome measures
Change from baseline in OCD symptomatology, as measured by the OCI-R (Obsessive Compulsive Inventory - Revised).
Change from baseline in aspects of mindfulness, as measured by the FFMQ (Five Facet Mindfulness Questionnaire).
Change from baseline in functional health and well-being, as measured by the SF-36 Health Survey (Short Form 36 item Health Survey).
+5 more
Other outcome measures
Change from baseline in OCD symptomatology, as measured by the EEG headset device "Muse".

MindOC Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Mindfulness-based Cognitive TherapyExperimental Treatment2 Interventions
This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.
Group II: Cognitive Behaviour TherapyExperimental Treatment1 Intervention
This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.
Group III: WaitlistActive Control1 Intervention
This study arm will not receive an intervention for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Behaviour Therapy (CBT)
2003
Completed Phase 3
~200
Mindfulness-Based Cognitive Therapy (MBCT)
2014
N/A
~180

Find a Location

Who is running the clinical trial?

McMaster UniversityOTHER
884 Previous Clinical Trials
2,597,896 Total Patients Enrolled
6 Trials studying Obsessive-Compulsive Disorder
221 Patients Enrolled for Obsessive-Compulsive Disorder
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,345 Previous Clinical Trials
26,453,147 Total Patients Enrolled
4 Trials studying Obsessive-Compulsive Disorder
546 Patients Enrolled for Obsessive-Compulsive Disorder
Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,550,888 Total Patients Enrolled
9 Trials studying Obsessive-Compulsive Disorder
390 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Cognitive Behaviour Therapy (CBT) Clinical Trial Eligibility Overview. Trial Name: NCT04914923 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Mindfulness-based Cognitive Therapy, Waitlist, Cognitive Behaviour Therapy
Obsessive-Compulsive Disorder Clinical Trial 2023: Cognitive Behaviour Therapy (CBT) Highlights & Side Effects. Trial Name: NCT04914923 — N/A
Cognitive Behaviour Therapy (CBT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04914923 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially qualify to participate in this experiment?

"Patients ages 18 to 65 with a current diagnosis of OCD can take part in this medical trial. Participation is contingent on the following conditions being met: participants must be taking an adequate daily dose (40mg/day) and duration (8 weeks minimum) of fluoxetine, as well as having a Yale-Brown Obsessive Compulsive Scale score exceeding 17."

Answered by AI

Are there any open enrolment opportunities for this medical trial?

"As of the most recently updated information on clinicaltrials.gov, this medical trial has concluded its recruitment phase, which began in September 2021. Despite not looking for participants anymore, there are over 100 other studies that can be accessed at present."

Answered by AI

Does this research protocol have a minimum age requirement?

"This particular medical trial is open to participants aged 18-65. There are 23 studies for minors and 67 trials available for those 65 years or older."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
St. Joseph's Healthcare Hamilton
What portion of applicants met pre-screening criteria?
Did not meet criteria
~149 spots leftby Sep 2025